Drug intelligence / Profile preview

Debio 0826

Development stage: Preclinical
Lead developer: Debiopharm
Modality: Peptides

Overview

Debio 0826 is an early-stage, venom-derived peptide oncology program being developed by Debiopharm that aims to target an innovative, undisclosed cancer pathway using a “venomics” and reverse-discovery approach. The lead peptide candidate originated from animal venom identified through a collaboration between Atheris, Debiopharm and the Ecole polytechnique fédérale de Lausanne, and is being optimized to improve drug-like properties such as efficacy, potency, selectivity, stability and reduced toxicity for potential use as a peptide anticancer drug.[1][10][13][5][11]

Beyond the preview

Go deeper on Debio 0826.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debio 0826.